221 related articles for article (PubMed ID: 35802645)
1. Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
Sayed S; Sidorova OA; Hennig A; Augsburg M; Cortés Vesga CP; Abohawya M; Schmitt LT; Sürün D; Stange DE; Mircetic J; Buchholz F
Cancer Res; 2022 Sep; 82(17):3002-3015. PubMed ID: 35802645
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
3. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells.
Lee W; Lee JH; Jun S; Lee JH; Bang D
Sci Rep; 2018 Aug; 8(1):11879. PubMed ID: 30089886
[TBL] [Abstract][Full Text] [Related]
4. A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.
Sinha S; Barbosa K; Cheng K; Leiserson MDM; Jain P; Deshpande A; Wilson DM; Ryan BM; Luo J; Ronai ZA; Lee JS; Deshpande AJ; Ruppin E
Nat Commun; 2021 Nov; 12(1):6512. PubMed ID: 34764240
[TBL] [Abstract][Full Text] [Related]
5. CRISPR prime editing for unconstrained correction of oncogenic KRAS variants.
Jang G; Kweon J; Kim Y
Commun Biol; 2023 Jun; 6(1):681. PubMed ID: 37391511
[TBL] [Abstract][Full Text] [Related]
6. Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
Tsukumo Y; Naito M; Suzuki T
PLoS One; 2020; 15(3):e0229712. PubMed ID: 32130260
[TBL] [Abstract][Full Text] [Related]
7. A CRISPR-Cas9 repressor for epigenetic silencing of KRAS.
Liu J; Sun M; Cho KB; Gao X; Guo B
Pharmacol Res; 2021 Feb; 164():105304. PubMed ID: 33202255
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-Mediated Knock-Out of Kras
Lentsch E; Li L; Pfeffer S; Ekici AB; Taher L; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739488
[TBL] [Abstract][Full Text] [Related]
9. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
[TBL] [Abstract][Full Text] [Related]
10. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Editing of the
Mirgayazova R; Khadiullina R; Chasov V; Mingaleeva R; Miftakhova R; Rizvanov A; Bulatov E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32630614
[TBL] [Abstract][Full Text] [Related]
12. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
14. CRISPR and KRAS: a match yet to be made.
Bender G; Fahrioglu Yamaci R; Taneri B
J Biomed Sci; 2021 Nov; 28(1):77. PubMed ID: 34781949
[TBL] [Abstract][Full Text] [Related]
15. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
Tsuchida N; Murugan AK; Grieco M
Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.
Schofield HK; Zeller J; Espinoza C; Halbrook CJ; Del Vecchio A; Magnuson B; Fabo T; Cali Daylan AE; Kovalenko I; Lee HJ; Yan W; Feng Y; Karim SA; Kremer DM; Kumar-Sinha C; Lyssiotis CA; Ljungman M; Morton JP; Galbán S; Fearon ER; Pasca di Magliano M
JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367463
[TBL] [Abstract][Full Text] [Related]
17. A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.
Budagyan K; Chernoff J
Methods Mol Biol; 2021; 2262():323-334. PubMed ID: 33977487
[TBL] [Abstract][Full Text] [Related]
18. Mathematical modeling the order of driver gene mutations in colorectal cancer.
Li L; Hu Y; Xu Y; Tang S
PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
[TBL] [Abstract][Full Text] [Related]
19. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.
Le Roux Ö; Pershing NLK; Kaltenbrun E; Newman NJ; Everitt JI; Baldelli E; Pierobon M; Petricoin EF; Counter CM
Elife; 2022 Sep; 11():. PubMed ID: 36069770
[TBL] [Abstract][Full Text] [Related]
20. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
